The fight over the lucrative market for rheumatoid arthritis drugs is heating up. In the last five years, three similar drugs have been introduced that offer patients the promise of getting back on their feet. Now the manufacturers of all three are jockeying for market share so they can be the leader when Medicare's full prescription drug benefit takes effect ...